FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
MONDAY, Aug. 8, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low breast cancer.
HER2-low is a new subclassification within HER2-negative, describing breast cancer that has some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. HER2-low patients are eligible for Enhertu if they have received a prior chemotherapy for metastatic disease or their cancer returned during adjuvant chemotherapy or within six months of completing chemotherapy.
The approval is based on results from the randomized DESTINY-Breast04 trial, in which 373 patients received Enhertu every three weeks and 184 received physician's choice of chemotherapy. Both progression-free survival and overall survival improved in patients with unresectable or metastatic HER2-low breast cancer receiving Enhertu. Nausea, fatigue, alopecia, vomiting, constipation, decreased appetite, musculoskeletal pain, and diarrhea were the most common adverse reactions.
"Today's approval highlights the FDA's commitment to be at the forefront of scientific advances, making targeted cancer treatment options available for more patients," Richard Pazdur, M.D., director of the FDA Oncology Center of Excellence, said in a statement. "Having therapies that are specially tailored to each patient's cancer subtype is a priority to ensure access to safe and innovative treatments."
Approval of Enhertu was granted to Daiichi Sankyo.
Related Posts
Observan un marcado aumento en los niveles de contaminación atmosférica en los últimos años
JUEVES, 21 de abril de 2022 (HealthDay News) -- Tras 23 años de reducciones en...
21 States Sue to Overturn CDC’s Public Transport Mask Mandate
WEDNESDAY, March 30, 2022 (HealthDay News) -- The U.S. government's mask mandate...
Ebola Vaccine Effective in African Clinical Trial
TUESDAY, Sept. 14, 2021 (HealthDay News) -- An experimental Ebola vaccine...
CDC Will Stop Issuing Daily Updates of COVID-19 Cases, Deaths
FRIDAY, Oct. 7, 2022 (HealthDay News) -- The U.S. Centers for Disease Control...